Complement Therapeutics
Generated by Meeveem AI
"Developing gene and protein therapies for complement mediated eye and systemic diseases"
London
•11 - 50 Employees
•Biotechnology
About Complement Therapeutics
Complement Therapeutics develops therapies for diseases driven by complement system dysregulation, a critical immune component. Born from world leading research at the University of Manchester, the company translates insights into treatments for high unmet clinical needs. The lead programme, CTx001, is an AAV gene therapy targeting geographic atrophy, the leading cause of irreversible vision loss in age related macular degeneration. The company pursues gene and protein based platforms alongside a proprietary mass spectrometry system that measures complement proteins for patient stratification. This precision medicine approach enables targeted treatment for patients with complement mediated diseases where current options remain limited.
34
Team Members
2021
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where complement mediated diseases are precisely understood, effectively treated, and no longer cause irreversible loss of function or quality of life for patients.
Our Mission
Complement Therapeutics exists to transform powerful complement system research into innovative therapies that address unmet needs in diseases caused by complement dysregulation.